Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: Implications as a potential biomarker
Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: Implications as a potential biomarker
复制标题
DOI：
10.1002/ijc.20716
复制
发表时间：
2005-03-20
影响因子：
6.4
通讯作者：
Belldegrun, AS
中科院分区：
文献类型：
--
作者：
Zeng, G;Aldridge, ME;Belldegrun, AS
监测癌症患者对一组相关肿瘤相关抗原（TAA）的自发抗体（Ab）反应，可提供有关癌症临床状态的有用信息。然而，目前的Ab检测方法需要纯化重组蛋白，这通常难以实现。为了绕过重组蛋白的纯化，我们从共享的肿瘤抗原NY-ESO-1中鉴定了一个优势B细胞表位。ESO：1-40抗原表位的合成肽在大多数患者中检测抗NY-ESO-1抗体的敏感性与重组蛋白相当。在黑色素瘤、前列腺癌、非小细胞肺癌、食管癌、胃癌和肝细胞癌患者血清中存在的NY-ESO-1特异性抗体与优势肽的反应频率与重组蛋白相似。据我们所知，ESO：1-40是第一个被来自广泛的癌症患者而不是健康供体的血清识别的肽表位。这种简单而直接的方法可以允许调查的临床意义的自发抗体反应对多种TAA和它们的相关性与恶性疾病的临床过程中的未来。(C)2004威利-利斯公司
Monitoring the spontaneous antibody (Ab) response against a panel of relevant tumor-associated antigens (TAA) in cancer patients may provide useful information regarding the clinical status of cancer. However, current Ab detection approaches require the purification of recombinant proteins, which is often difficult to achieve. In order to bypass the purification of recombinant proteins, we identified a dominant B-cell epitope from a shared tumor antigen NY-ESO-1. A synthetic peptide of the epitope, ESO:1-40, was as sensitive as the recombinant protein for detecting Ab against NY-ESO-1 in most patients. NY-ESO-1 specific Ab present in the sera of patients with melanoma, prostate cancer, nonsmall cell lung cancer, esophageal cancer, gastric cancer and hepatocellular carcinoma reacted with the dominant peptide at a similar frequency as the recombinant protein. To our knowledge, ESO: 1-40 is the first peptide epitope recognized by sera from a wide spectrum of cancer patients but not healthy donors. This simple and straightforward approach may allow the investigation of the clinical significance of spontaneous Ab responses against multiple TAA and their correlation with the clinical course of malignant diseases in the future. (C) 2004 Wiley-Liss, Inc.